Skip to main content
Premium Trial:

Request an Annual Quote

MIT's Koch Institute to Use Roche LightCycler 480 in Research


This article, originally published on April 6, has been updated from a previous version to include additional information and comments from a Roche spokesperson.

Roche said today that the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology will use a Roche LightCycler 480 real-time PCR system in its research.

Researchers at the institute will use the platform to analyze gene expression and genetic variation in cancer research, Roche said.

More specifically, the Koch Institute plans to use the platform "to support several key areas of research it has identified as being critical for rapid progress toward controlling cancer, such as exploring the molecular and cellular basis of metastasis and engineering the immune system to fight cancer," the company said in a statement.

The Koch Institute was conceived in 2007 with a $100 million gift from MIT alumnus David Koch, transforming the former MIT Center for Cancer Research into a highly multidisciplinary cancer research institute.

A Roche spokesperson told PCR Insider that the institute plans to use several LightCycler 480 instruments throughout its facility, but that it is too early to identify specific research applications in which researchers will be using real-time PCR.

"The LightCycler instruments will provide the platform to help us take advantage of the many applications for real-time PCR technology in cancer research," Robert Urban, executive director of the Koch Institute, added in a statement.

The LightCycler 480 is a fully integrated, 96- and 384-well plate-based real-time PCR platform for the qualitative and quantitative detection of nucleic acids. It can be used in a broad range of research applications, such as gene expression studies, discovery and analysis of genetic variation, or array data validation, Roche said.

Financial terms of the agreement were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.